Search
for
Sort by
Research 361–390 of 1000+
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- 1H NMR-based lipidomics of rodent fur: species-specific lipid profiles and SCD1 inhibitor-related dermal toxicity
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- A review of Janus kinase inhibitor use in scarring alopecia
- Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Enzyme Inhibitors from Gorgonians and Soft Corals
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Bacterial cellulose/soybean protein isolate composites with promoted inflammation inhibition, angiogenesis and hair follicle regeneration for wound healing
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
- CDK4/6 plus aromatase inhibitor-induced alopecia in breast cancer patients.
- Steroid inhibitors of androgen-potentiated actions on skin
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Tanshinone, a Natural NADPH Oxidase Inhibitor, Mitigates Testosterone-Induced Hair Loss
- Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
- Cardamonin inhibits the expression of inflammatory mediators in TNF-α-stimulated human periodontal ligament cells
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
- Therapeutic inhibition of keratinocyte TRPV3 sensory channel by local anesthetic dyclonine
- The use of phosphodiesterase inhibitors for the treatment of alopecia
- iNOS inhibits hair regeneration in obese diabetic (ob/ob) mice
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Partial Proteasome Inhibitors Induce Hair Follicle Growth by Stabilizing β-Catenin
- “Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- FINASTERIDE INHIBITS 5?-REDUCTASE ACTIVITY IN HUMAN DERMAL FIBROBLASTS: PREDICTION OF ITS THERAPEUTIC APPLICATION IN ANDROGEN-RELATED SKIN DISEASES
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study